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Proteogenomic integration reveals therapeutic
targets in breast cancer xenografts
Kuan-lin Huang1,2,*, Shunqiang Li1,*, Philipp Mertins3,*, Song Cao2, Harsha P. Gunawardena4, Kelly V. Ruggles5,
D.R. Mani3, Karl R. Clauser3, Maki Tanioka6, Jerry Usary6, Shyam M. Kavuri7, Ling Xie4, Christopher Yoon1,2,
Jana W. Qiao3, John Wrobel4, Matthew A. Wyczalkowski2, Petra Erdmann-Gilmore1, Jacqueline E. Snider1,
Jeremy Hoog1, Purba Singh7, Beifang Niu2, Zhanfang Guo1, Sam Qiancheng Sun1,2, Souzan Sanati8,
Emily Kawaler5, Xuya Wang5, Adam Scott2, Kai Ye2,9, Michael D. McLellan2, Michael C. Wendl2,9,10,
Anna Malovannaya7,11, Jason M. Held1,12,13, Michael A. Gillette3, David Fenyo¨5, Christopher R. Kinsinger14,
Mehdi Mesri14, Henry Rodriguez14, Sherri R. Davies1, Charles M. Perou6, Cynthia Ma1,12, R. Reid Townsend1,12,
Xian Chen4, Steven A. Carr3, Matthew J. Ellis7 & Li Ding1,2,9,12
Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer
proteomes. Here, we employed quantitative proteomics to proﬁle protein expression across
24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis
shows positive correlation between expression measurements from transcriptomic and
proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitu-
lated using non-stromal protein markers. Proteogenomic analysis also validates a number of
predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/
phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1
phosphosites are not readily explainable by genomic analysis, suggesting that druggable
translational and/or post-translational regulatory events may be uniquely diagnosed by MS.
Drug treatment experiments targeting HER2 and components of the PI3K pathway supported
proteogenomic response predictions in seven xenograft models. Our study demonstrates that
MS-based proteomics can identify therapeutic targets and highlights the potential of PDX
drug response evaluation to annotate MS-based pathway activities.
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P
roﬁling of somatic alteration by next-generation DNA
sequencing (NGS) has entered clinical practice with the
promise of rapid diagnosis of druggable somatic genomic
alterations for personalized cancer treatment1,2. For example,
recent analysis of 4,068 samples from 16 cancer types suggested
that repurposing approved drugs based on genomic alterations
could provide individualized treatment options for around 40% of
tumours3. However, clinical evidence for this proposition is
limited and has been slow to develop. Further, the signalling and
biological effects of somatic mutations are not routinely
determined in human tumour samples even though this is a
consideration for rational drug design, response prediction and
target prioritization4,5. Finally, druggable genomic alterations are
not detected in the majority of cases tested by NGS3.
Comprehensive proteomic analyses provide a potentially
valuable approach to validate genomic ﬁndings as likely
biological drivers and to discover discover opportunities for
targeted treatment.
Patient-derived xenografts (PDXs) in immunodeﬁcient mice
maintain the histological and molecular heterogeneity of the
progenitor human tumour6 and cytotoxic drug responsiveness is
often a transplantable phenotype7. Our previous studies have
shown that breast tumour PDXs recapitulate major genomic
signatures and transcriptome proﬁles of their original breast
tumours8,9. Moreover, drug responses to endocrine therapy in
breast cancer PDXs resembled that observed in the corresponding
patient and endocrine therapy resistance patterns were associated
with aberrations in the ESR1 gene6. While comprehensive
proteomic characterization of PDX is still lacking, recent
studies using reverse phase protein array have identiﬁed similar
protein proﬁles between PDX and primary tumours10,11. These
studies collectively suggest that the PDX approach is a potentially
valuable preclinical model for identiﬁcation and testing of
therapeutic targets.
Recent advances in mass-spectrometry provide an unprece-
dented opportunity for antibody-independent proteome proﬁling
with approximately 80% of all proteins in major human tissues
quantiﬁable by this technique12. Analyses of the global proteome
in tandem with genomic proﬁles generated through TCGA have
yielded key insights on the molecular etiology of colorectal
cancer13, breast cancer14 and ovarian cancer15. Our recent
proteogenomic characterization of 105 human breast cancers
linked 5q-loss to elevated EGFR expression and identiﬁed
overexpression of phosphorylated kinases including CDK12,
PAK1 and ARAF as potential biological drivers14. However,
current proteogenomic analyses of human tissues are limited by
the fact that therapeutic hypotheses were not being addressed in
these initial analyses. As patient treatments were heterogeneous,
links between treatment and proteogenomic ﬁndings are difﬁcult
to establish in banked tumour specimens. The PDX system
therefore provides an early opportunity to determine whether a
proteogenomic approach can produce more robust therapeutic
hypotheses and predictive biomarkers for individual patients than
that achieved by genomic analysis alone.
In this study, we generated high-coverage proteome and
phosphoproteome data for 24 PDX models representing different
breast cancer subtypes using both isobaric mass-tag labelling and
label-free proteomic methods for cross-validated identiﬁcation of
12,794 proteins and 56,874 phosphorylation sites. After ﬁltering
for observation in at least 10 out of 24 samples 10,069 proteins
and 36,609 phosphorylation sites with their relative abundances
quantiﬁed across tumours, were used in subsequent analyses in
this study. A substantial number of druggable protein/phospho-
protein events were uniquely identiﬁed. Further, similar proteo-
mic/phosphoproteomic signatures were observed in patient breast
cancer samples indicating potential clinical relevance. In selected
PDX models exhibiting proteomic and/or phosphoproteomic up-
regulation events of HER2 or the PI3K pathway, we validated the
efﬁcacy of targeted inhibitors in suppressing PDX growth. Taken
together, these observations show that comprehensive proteoge-
nomic proﬁling has potential to identify new targets for
individualized treatment approaches in cancer.
Results
Proteogenomic coverage of breast cancer xenografts. We
selected 24 PDX models established from primary or metastatic
breast tumours for comprehensive proteogenomic characteriza-
tion (Fig. 1a). The human patient cohort was composed of 10
basal, 1 claudin-low (CLDN-low), 9 luminal B and 4 HER2-
enriched (HER2-E) breast tumours based on PAM50 expression
subtyping (Supplementary Data 1). We conducted DNA and
RNA sequencing respectively for 23 PDX models and in one case
Sanger DNA sequencing of hotspot mutations. Isotope Tagging
for Relative and Absolute Quantitation (iTRAQ 4-plex)16 was
completed for all 24 PDXs for discovery and label-free
quantiﬁcation (LFQ) for 18 PDXs for validation and
conﬁrmation (Supplementary Data 2). The comprehensive
proteogenomic coverage allowed us to systematically assess the
somatic mutation proﬁle, copy-number variation (CNV), mRNA
expression, protein expression, and phosphosite levels and
localizations.
We examined somatic mutations in signiﬁcantly mutated genes
of breast cancer in 12 human tumours and their matching PDXs
(Supplementary Data 2). Most key somatic mutations in these
genes were preserved (Fig. 1b), validating the genomic ﬁdelity of
these PDX models. However, recurrent breast cancer mutations
were not detected in two PDX models (WHIM17 and WHIM46).
While sequencing data were not available for the matched
progenitor human tumours, the germline SNPs of human blood
normal samples matched with the PDX tumours, validating their
patients of origin. Follow-up histological and RNA-seq analyses
suggested WHIM17 and WHIM46 are EBV-positive human
lymphoproliferative cells arising in the NOD/SCID/g mouse
strain17 (Methods, Supplementary Fig. 1).
We then compared the variant allele fractions (VAFs) of exonic
somatic mutations in human tumours and derived xenografts
when both are available. We found comparable or higher VAFs in
xenografts, potentially due to higher tumour purity and selection
of some mutant alleles by loss of heterozygosity in PDX models
(Fig. 1c). The relatively high, positive VAF correlation (R¼ 0.66)
implied similarity between human samples and their respective
xenografts, consistent with our previous report9. Importantly, all
PIK3CA and TP53 somatic mutations in the 12 originating
human tumours were detected in respective xenografts with
comparable or increased VAFs (Fig. 1c). Among the 22 breast
cancer PDX models, 14, including 7 of the 8 basal tumours,
harboured TP53 mutations, 5 luminal B PDXs had ESR1
mutations, and 5 luminal B and 1 CLDN-low xenografts
carried PIK3CA mutations.
We quantiﬁed mRNA expression of 16,209 unique human
genes from RNA-seq data for these 24 models. We also applied
two distinct MS data acquisition approaches (Supplementary
Fig. 2a, Methods), iTRAQ (Supplementary Data 3) and LFQ
(Supplementary Data 4), to quantify the expression ratios of
12,794 human proteins (11,879 genes) and 8,648 proteins (8,035
genes), respectively. A total of 56,874 phosphosites were also
conﬁdently identiﬁed using iTRAQ (Supplementary Data 5).
After ﬁltering for observation in at least 10 out of 24 samples
(4 out of 9 of the iTRAQ experiments, Supplementary Fig. 3), the
relative abundances of 10,069 proteins and 36,609 phosphoryla-
tion sites were quantiﬁed across tumours by iTRAQ and used in
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subsequent analyses in this study. The technical replicates in the
LFQ (WHIM2 and WHIM16) and the iTRAQ (WHIM13) sets
showed high correlation in protein expression levels (R40.85,
Supplementary Fig. 2b,c,e). Further, phosphosite expressions
also showed high correlations in technical replicates (WHIM13)
of the iTRAQ experiment (R¼ 0.82, Supplementary Fig. 2d),
validating the technical reproducibility of our proteomic and
phosphoproteomic datasets. Of note, while iTRAQ and LFQ
quantiﬁcation were conducted separately and based on different
features of the LC–MS data collected from the Q Exactive
mass spectrometer (that is, reporter ion intensity and MS1 peak
area, respectively), our analysis showed reasonable correlation
between the two measurements after normalization (R¼ 0.61).
The two datasets utilizing the same PDX models but different
workﬂows enabled cross-method validation of global proteomic
results.
Proteogenomic integration and comparison. We ﬁrst evaluated
the correlation between mRNA expression and protein abun-
dance measurements from the iTRAQ experiment (Fig. 2a) for
these 24 PDX models: 83.6% of the genes with sufﬁcient data
showed positive correlations with a median Pearson R¼ 0.536
(Supplementary Fig. 4). We investigated whether the trend of
mRNA-protein correlations were associated with speciﬁc KEGG
pathways18, ﬁnding that metabolic pathways involved in house-
keeping functions are enriched for genes showing high, positive
correlation. For example, genes in the glutathione metabolism
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Figure 1 | Modelling human breast cancer with patient-derived xenografts (n¼24). (a) Illustration of generation and proteogenomic characterization of
breast cancer xenograft models. (b) Somatic mutations of signiﬁcantly mutated genes of human breast tumour were recapitulated in xenograft models.
Mutation data for 23 WHIMs are shown (exome data were not available for WHIM47). (c) Variant allele fraction analysis showed clonal representation
was consistent between human breast tumour and xenografts. Genomic driver events, including missenses and truncations in TP53 and PIK3CA, were
retained in the xenograft models. Each colour represents one xenograft sample.
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Figure 2 | Proteogenomic correlation analysis in PDX samples. (a) Correlation between mRNA and iTRAQ protein expression levels identiﬁed pathways
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pathway showed the highest enrichment for positive correlations
(Kolmogorov–Smirnov test, false discovery rate (FDR)¼ 5.6e-07).
Interestingly, we observed that genes in the ribosome
(FDRo2.2e-16), spliceosome (FDR¼ 2.0e-13), RNA transport
(FDR¼ 1.7e-5), RNA polymerase (FDR¼ 1.8e-4), and oxidative
phosphorylation (FDRo2.2e-16) pathways showed relatively
lower correlation between mRNA and protein level. These
pathways were enriched for genes that do not require translated
proteins for their biological functions. Similar pathway-speciﬁc
pattern of positive and negative enrichment of correlations were
observed by LFQ (Supplementary Fig. 5). The high degree of
mRNA–protein correlation observed in the PDX samples is
consistent with recent results obtained for human breast
tumours14 and colorectal cancer13, suggesting that PDXs closely
mimic the respective human breast tumours in their relationship
between mRNA and protein.
We then examined the correlation of CNV, mRNA, and
protein expression levels for several key genes for breast cancer
biology: EGFR, ERBB2 (HER2), ESR1, GATA3, PGR, PIK3CA,
AKT1/2/3, MTOR and TP53. In most cases, we observed
consistent relationships between CNV, mRNA, and protein
expression levels. Compared with PDXs of non-luminal subtypes,
luminal B breast cancer xenografts, as expected, showed higher
mRNA and protein expression of ESR1 and PGR, consistent with
their positive ER and PR status (Fig. 2b). Five out of the six
PIK3CA mutations were observed in luminal B PDXs, which
tended to also show higher mRNA and protein expression
levels of GATA3. In contrast, a larger proportion of basal
PDXs expressed higher protein levels of EGFR. Strong HER2
expression at the mRNA, protein and phosphoprotein levels
were detected in WHIM8 and WHIM35, both derived from
HER2-positive breast cancers. Overall expression patterns for key
genes were consistent with the clinical subtype diagnosis across
CNV, mRNA, protein and phosphosite analyses (Supplementary
Fig. 6).
Proteomic subtyping of xenografts and human breast tumours.
Molecular subtyping of breast cancer based on mRNA expression
proﬁles has been shown to correlate with prognosis and has
treatment implications19,20. As expected, transcriptome clustering
based on PAM50 genes from RNA-seq data largely reproduced
intrinsic subtypes of the breast tumours (Fig. 3a; Supplementary
Data 6). To explore proteomic and phosphoproteomic subtype
classiﬁcations in xenograft models, we conducted unsupervised
clustering of proteomes and phosphoproteomes of the 24
xenograft samples based upon the top 436 variably expressed
proteins showing a s.d. greater than 2 from the iTRAQ proteome
(Supplementary Data 7). Two distinct clusters emerged: one
contained all basal tumours and the only CLDN-low tumour
(WHIM12), while the other included all luminal B and HER2-E
breast tumours; HER2-E tumours did not show a proteomic
expression proﬁle distinct from luminal B samples (Fig. 3b).
Clustering analysis using the same gene markers from the
transcriptome (Supplementary Fig. 7a) and the LFQ proteome
(Supplementary Fig. 7b; Supplementary Data 8) further
supported the separation into these two proteomic subtypes,
although the minor differences between the transcriptome and
the proteome clustering suggested distinctions between mRNA
and protein levels. The proteomic subtypes deﬁned by the top 968
most variably expressed mouse host proteins did not segregate
based on luminal and basal subtypes (Supplementary Fig. 8;
Supplementary Data 9). Besides differing in mRNA expression,
luminal and basal breast cancer PDXs also showed consistently
distinct proteomic expression proﬁles, supporting their distinct
biological origins.
We then utilized the iTRAQ phosphopeptide expression data
to infer phosphoproteomic subtypes. 1,737 unique phosphosites
with s.d. greater than 2.5 were included to conduct hierarchical
clustering (Fig. 3c; Supplementary Data 10). These analyses of the
phosphoproteomic data produced two major clusters segregating
the luminal B and basal subtypes. Again, the WHIM37/
WHIM47/WHIM26 group and the WHIM17/WHIM46 group,
as observed in the proteome clustering, grouped closely together.
Gene and protein expression of lymphoid lineage markers
showed high expression of CD20 and JAK3 in WHIM17 and
WHIM46 (Methods, Supplementary Fig. 9), consistent with their
positive EBV status and histological diagnosis (Supplementary
Fig. 1) as human lymphoproliferative cells arising in an
immunocompromised mouse background. Overall, while the
basal and luminal clusters remain consistent, the hierarchical
distances between PDX samples within the two major clusters
differ between data types. The departure of proteomic and
phosphoproteome subtypes from mRNA expression-deﬁned
subtypes suggests independent layers of molecular heterogeneity
provided by distinct proteomic analyses.
We then investigated whether human proteomic subtypes
could be recapitulated in PDX models by including an additional
77 proteomes from TCGA human tumours that were processed
concurrently in the iTRAQ experiment14 (Methods). To reduce
clustering bias imbued by the mouse contribution to the
proteome in the PDX samples, we excluded proteins showing
differential expression between human tumour and xenograft
(t-test, FDRr0.3) (Supplementary Data 11). Additional
requirements, including the presence of detectable protein in
more than 10 samples and minimum difference of 2 s.d.’s in the
merged proteome, resulted in 133 proteins qualifying for un-
supervised clustering. Consistent with the subtyping analysis of
the 24 PDXs alone, we identiﬁed two major clusters: one that
included all but one basal breast tumour and the other comprised
mostly of luminal tumours (Fig. 3d). Similar to the proteomic
subtypes of the PDX cohorts, luminal tumours and HER-2
tumours did not show clear separation, although several sub-
clusters were identiﬁed. Importantly, xenograft proteomes
clustered adjacently to the human proteomes of their respective
subtypes, validating the ﬁdelity of basal and luminal proteomic
signatures discovered in PDXs.
To search for deﬁning markers between the basal and luminal
B subtypes, we conducted differential expression analysis between
the PDXs of the respective subtypes. We found several proteomic
markers that were differentially expressed in both the LFQ and
iTRAQ datasets (t-test, FDRr0.05), including SPR, GSTP1 and
SERPINB5 (Supplementary Fig. 10; Supplementary Data 12). We
then conducted gene-set enrichment analysis based on the
Reactome pathway database21 to investigate patterns of
differential expression (Methods). The basal subtype breast
tumours were up-regulated in most of the signiﬁcantly
differentially-expressed pathways (FDRr0.01) identiﬁed by
both LFQ and iTRAQ datasets, including extracellular matrix
organization, cell cycle, and collagen formation. In comparison,
the luminal B breast tumours showed higher expression in genes
related to organelle biogenesis and membrane trafﬁcking
(Supplementary Data 13).
Activated pathways revealed by phosphorylation proﬁles.
Cancer driving somatic events trigger major changes in down-
stream signalling to launch the tumorigenic cascade22. To search
for tumour-speciﬁc activated pathways in PDX tumours, we
systematically evaluated and compared phosphoproteome proﬁles
of gene sets from KEGG signalling pathways (Methods).
Phosphorylation enrichment analysis identiﬁed 12 signiﬁcantly
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activated pathways, including Ras, MAPK and NFkB signalling,
in 4 xenografts (FDRr0.01, Supplementary Data 14). WHIM9
exhibited elevated phosphorylation of the MAPK signalling
pathway (FDR¼ 9.69e-6; Fig. 4a). Interestingly, WHIM9 carried
a recurrent somatic mutation, KRAS p.A146V (refs 23,24), which
may have driven canonical MAPK pathway activation. Further,
WHIM12 exhibited activation of the Ras signalling pathway
(FDR¼ 4.28e-5), along with an outlier protein expression of
MET, a receptor tyrosine kinase upstream of the Ras signalling
pathway (Fig. 4b). Interestingly, WHIM17 and WHIM46, both
harboured BTK and PLCG2 protein overexpression, exhibited
overall high phosphorylation of the NFkB signalling pathway
(Fig. 4c,d; FDR¼ 6.94e-3, 4.53e-5 respectively). This observation
further supports the strong similarity between these two PDX
models based on protein/phosphoprotein clustering (Fig. 3b,c)
and their classiﬁcation as EBV-positive lymphoproliferation.
While pathways such as PI3K/AKT/MTOR are known to be
activated across the majority of breast tumours22, our analysis
shows that other complementary tumorigenesis-related pathways
including RAS/MAPK are also activated in a small set of breast
tumours due to speciﬁc genomic or proteomic alterations,
representing alternative treatment opportunities. In addition,
our phospho-proteomic analysis revealed activation of signalling
pathways not readily predicted by genomic data.
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Figure 3 | Transcriptomic and proteomic clustering of breast cancer PDX and human samples. (a) Transcriptomic clustering of PDX breast tumours
based on the PAM50 gene expression markers. (b) Proteomic clustering of PDX breast tumours based on the top 436 variably expressed proteins. (c)
Phosphoproteomic clustering of PDX breast tumours based on the top 1,737 variably expressed phosphosites. (d) Proteomic clustering using only 133 non-
differential expressed proteins between WHIM and human breast tumour samples. The clustering reproduced the basal-enriched and luminal-enriched
clusters, where PDX (n¼ 24) and TCGA human breast tumour samples (n¼ 77) cluster based on their subtypes. The non-differentially expressed proteins
were identiﬁed through a t-test with FDR40.3 between the PDX and the TCGA human tumour samples. The PDX tumours are labelled by their WHIM IDs
whereas the human tumours are not labelled.
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Complementary genomic/proteomic druggable targets. We
examined promising drug targets in each tumour by surveying the
genome and expressed proteomes. Speciﬁcally, we compiled a list 76
druggable genes (Supplementary Data 15), along with their respective
drugs, from established public databases (Methods). Six PDXs,
representing 20.8% of the tumours in this study, harboured druggable
somatic mutations, including PIK3CA p.H1047R and KRAS p.A146V
in WHIM9, PIK3CA p.H1047R in WHIM16 and WHIM24, PIK3CA
p.E545K in WHIM18, PIK3CA p.E542K in WHIM20 and SF3B1
p.K700E in WHIM26 (Supplementary Data 16).
While activating mutations in oncogenes can be targeted by
treatments, aberrantly overexpressed or activated protein pro-
ducts, such as HER2, also presents exploitable treatment
opportunities25–27. We sought genomic and proteomic evidence
of overexpressed genes/proteins or proteins with highly
phosphorylated sites. We deﬁned outliers as expression values
exceeding the 1.5 interquartile ranges (IQR) above the third
quartile of the cohort (Variations of Box Plots), and rank ordered
them by the outlier score. We further required CNV outliers to be
validated with outlier expression in either the mRNA or protein
level to rule out up-regulation events due to technical artifacts or
passenger events (Methods). mRNA and protein expression
outlier scores showed a moderate positive correlation (Fig. 5a,
R¼ 0.516), but mRNA outlier expression did not guarantee high
protein expression (for example, AKT2 and FGFR2, Fig. 5a).
Similarly, we observed a fraction of phosphosite outliers not
detected at the protein level (Fig. 5b, R¼ 0.548). Consequently,
identifying post-transcriptional and post-translational events to
capture potential druggable treatment opportunities requires
consideration of protein expression as well as gene expression.
Applying this druggable outlier detection strategy across CNV,
mRNA, protein and protein phosphorylation levels, we identiﬁed
overexpressed druggable genes in 26.1% and 47.8% of PDXs at
the CNV and mRNA levels, respectively (Fig. 6; Supplementary
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Figure 4 | Activated signalling pathways detected through pathway phosphorylation enrichment analysis. (a) Activation of the MAPK signalling
pathway in WHIM9. (b) Activation of the Ras signalling pathway in WHIM12. (c) Activation of the NFkB pathway in WHIM17. (d) Activation of the NFkB
pathway in WHIM46. Phosphorylation levels of each protein in the pathway relative to the cohort of 24 PDX models are shown by the colour scale of red
(high) to blue (low). Proteins with no phosphorylation data are coloured in green.
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Data 16). These events recapitulated known druggable opportu-
nities, such as the PIK3CA copy-number ampliﬁcation in
WHIM4 and ERBB2 (HER2) copy-number ampliﬁcation in
WHIM35. Expanding to iTRAQ protein expression outliers
allowed us to uncover druggable targets in 19 out of the 24 PDXs
(79.2%), while considering phosphosite outliers covered 22 of the
24 PDXs (91.7%). A signiﬁcantly high fraction of protein outliers
overlapped between the LFQ and iTRAQ datasets (Fisher’s Exact
Test, P¼ 2.013e-05, Supplementary Fig. 11), providing validation
of our ﬁndings.
The identiﬁed proteomic outliers included multiple known
druggable targets involved in the PI3K, RTK, MAPK signalling
pathways and other oncogenic processes (Fig. 6; Supplementary
Data 16). For instance, HER2 was found to be the top outlier at the
protein expression level in 2 HER2-E xenografts, WHIM8 and
WHIM35; the phosphosites of HER2 were also identiﬁed as outliers.
Immunohistochemistry experiments validated the high HER2
protein expression on the cell membranes of WHIM8 andWHIM35
(Fig. 5c; Supplementary Fig. 12). Further, AKT1, AKT2 and AKT3
proteins were outlier expression candidates in WHIM35, WHIM20
and WHIM43 and WHIM4, respectively, providing proteomic
validation of previously observed AKT up-regulation at mRNA
expression level in breast cancer22. Other outlier proteins included
IDH1 in WHIM9 and WHIM30, FGFR4 in WHIM11 and
WHIM26, and both BTK and JAK3 in the EBV-positive
WHIM17 and WHIM46. Many of these protein outliers aligned
with up-regulation in their corresponding phosphosites, including
phosphosites on AKT1, AKT3, BRAF, FGFR4 and HSP90AB1
(Fig. 5c, selected phosphosite spectra in Supplementary Fig. 13). We
also discovered additional outlier phosphosites in other proteins
including CTNNB1, ARAF, and HSP90B1 (Supplementary Data
16). Finally, we identiﬁed outlier FGFR2 in WHIM16 and high
RAF1 in WHIM9 and further validated their high protein
expression status of by immunohistochemistry analyses (Fig. 5c;
Supplementary Fig. 12). As diverse sets of proteomic outliers are
identiﬁed across PDXs, effectively inhibiting such activation events
will be required when designing targeted treatment strategies to each
individual breast tumour.
Notably, for 80.6% of proteomic outlier events, we were able to
identify human tumours from the 77 TCGA samples14 showing
the same outlier protein expression through outlier score or
ranking (Methods, Fig. 6b, Supplementary Data 16). For example,
we observed outlier HER2 expression in ﬁve HER2-E and four
luminal B human breast tumours. Further, a basal human sample
carried both the outlier FGFR2 and FGFR4 expression, validating
the ﬁndings in WHIM16, WHIM26 and WHIM11. Basal
human breast tumours also carried protein expression outliers
in IDH1, EGFR and MAP2K1 (Fig. 6b). Phosphosite outlier
expression events showed a moderate rate of validation in the
same human cohort (48.8%, Fig. 6c), suggesting its transient
nature and potential micro-environmental effects on protein
phosphorylation. As expected, HER2-E and a few HER2-positive
luminal B tumours carried outliers in HER2 phosphosites
including p.T701, p.T1240 and p.Y1248. ARAF phosphosite
outliers, such as p.S299, were found in both human and PDX
samples, validating our previous ﬁnding in the human cohort12.
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Interestingly, we identiﬁed outlier phosphosites in genes not
previously implicated in breast cancer through genomic proﬁles,
such as BRAF p.S447, p.S750 and HSP90AB1 p.Y56 and p.S169
(Fig. 6c). Our results demonstrated that proteomic outlier events,
like genomic driver mutations, are consistently observed in PDXs
and human tumours. Some protein outlier events might represent
‘proteomic drivers’ of tumorigenesis and therefore potential drug
targets in breast tumours.
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Targeted treatments using breast cancer xenograft models. To
validate the identiﬁed druggable events, we conducted treatment
experiments targeting HER2 and PI3K pathways on selected PDX
models. Four PDX models were chosen to address HER2 tar-
geting using lapatinib, an oral HER2 kinase inhibitor. These
include 2 HER2-E PDX models WHIM8 and WHIM35, both
with high HER2 protein and phosphoprotein expression, and 2
low HER2 expressing, basal-like PDX models WHIM6 and
WHIM14. Western blotting suggested high HER2 expression and
phosphorylation of HER2 p.Y1248 in both HER2 positive
tumours, WHIM8 and WHIM35 (Fig. 7a; Supplementary
Fig. 14). Unexpectedly, high levels of HER2 p.Y1248 phosphor-
ylation was also detected in WHIM14 by western blotting. In
contrast MS-based phosphoproteomics also detected high levels
of HER2p.Y1248 in WHIM8 and WHIM35, but not in WHIM14,
which was more consistent with the known biology of the models.
Antibody-based diagnosis of HER2 activation in WHIM14
was possibly due to cross-reaction of the Y1248 antibody with
the pY1172 site of EGFR that bears high sequence similarity
around the pY residue (..GTPTAENPEy1248LGLDVPV-CO2H
vs...GSTAENAEy1172LRVAPQ.., Supplementary Fig. 6). As
expected, WHIM8 and WHIM35 were growth inhibited (Wil-
coxon Rank Sum Test, P¼ 2.7e-5, 4.8e-7) by lapatinib, whereas
WHIM6 was not (P¼ 0.65) (Fig. 7b). Interestingly, WHIM14 also
showed signiﬁcant reduction in tumour growth by lapatinib
(P¼ 4.3e-3). Upon further exploration with a lower, clinically
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Figure 7 | Targeted treatments of breast cancer xenografts. (a) Western blot of HER2 protein and HER2 p.Y1248 expression levels in 5 WHIM models
(WHIM6, WHIM8, WHIM12, WHIM14 and WHIM35). (b) In vivo treatment responses to lapatinib in 4 PDX models including two HER2 positive lines
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of WHIM16, WHIM18 and WHIM20 (n¼8-9 for each control or experimental group). Values were represented by average tumour volume (mm3) every
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achievable dose of lapatinib for chronic treatment (30mg kg 1
compared with 220mg kg 1 in the previous experiment) over 48
days, signiﬁcant but weak tumour growth inhibition was again
achieved (P¼ 0.0311, Supplementary Fig. 15). However,
WHIM14 did not respond to HER2/HER3 antibodies trastuzu-
mab or pertuzumab (P¼ 0.250 and 0.181, respectively;
Supplementary Fig. 15). Thus, the response of WHIM14 to
lapatinib was likely due to inhibition of EGFR not HER2
(refs 28,29). While WHIM6 also showed elevated EGFR protein
level, WHIM14 showed notably higher EGFR phosphorylation
based on both mass spectrometry (Fig. 2b) and western blotting
(Fig. 7a), which could account for their different response to
lapatinib. Two basal and one HER2-E human breast cancers
harboured outlier EGFR expression (Fig. 6b), suggesting EGFR
remains a potential therapeutic target in a subset of breast cancers
that has yet to be fully realized clinically.
The PI3K/AKT/mTOR signalling pathway is altered in
approximately 77% of breast tumours22 and multiple drugs
targeting its components, including Class I PI3Ks, AKTs, and
mTORs, are already in clinical trials30. Among these, a
combination of everolimus and exemestane has been approved
for treating advanced ER-positive breast cancers resistant to non-
steroidal aromatase inhibitors31. Promising activity has also been
reported for direct inhibitors of PI3K32,33. However, mutations in
PIK3CA and other genetic alterations at the genomic level have so
far failed to closely predict therapeutic responsiveness to PI3K
pathway inhibitors32. We therefore hypothesized that combined
genomic and proteomic indication of PI3K signalling activation is
necessary for the prediction of treatment response. Our integrated
approach identiﬁed 6 xenografts that harboured complementary
genomic and proteomic druggable events in the PI3K-AKT
pathway. In particular, WHIM16 harboured a hotspot PIK3CA
p.H1047R mutation, whereas WHIM18 and WHIM20 each
carried a hotspot PIK3CA p.E545K mutation. WHIM20 also
showed an additional outlier protein expression of AKT2 and
WHIM18 also expressed AKT2 at a near outlier level that may
combine to activate PI3K pathway signalling (Fig. 6). Since the
treatments were applied to later-passage PDX models relative to
the ones we conducted proteogenomic analysis on, we performed
immunohistochemistry to validate the phosphorylation of AKT
p.S473. WHIM18 and WHIM20 showed detectable AKT p.S473,
which was not observed in WHIM16 (Fig. 7c).
We conducted combinatorial treatment experiments by apply-
ing an alpha speciﬁc PI3K inhibitor (TAK-117) and/or an
mTORC1/2 inhibitor (TAK-228) to three PDX models of luminal
B breast cancer. Consistent with previous reports, PIK3CA
mutation status alone did not accurately predict outcome;
WHIM18 and WHIM20 showed reduced tumour growth upon
application of the inhibitors, whereas WHIM16 did not (Fig. 7d).
mTOR inhibition repressed tumour growth in WHIM18
and WHIM20 (ANOVA followed by Tukey’s post hoc test,
P¼ 9.5e-10, 1.6e-03 respectively), but not in WHIM16 (P¼ 0.97),
showing that inhibition of mTORC1/2 may effectively suppress
breast tumours with activated AKTs and validating a previous
study showing the efﬁcacy of mTOR inhibition in PDX models of
triple-negative breast cancer34. Importantly, the combinatorial
treatment achieved the greatest effect in WHIM18 and WHIM20
(Po2.2e-16 for both comparisons). While neither PI3K nor
mTOR inhibitor drug treatment alone suppressed tumour growth
in WHIM20 completely, the combination of both PI3K and
mTOR inhibitors signiﬁcantly reduced tumour growth to a nearly
static state (Fig. 7d). Based on our proteomic characterization,
WHIM20 exhibited the strongest AKT1 and AKT2 protein
expression, as well as AKT1 p.S122 and p.S475 phosphorylation
signatures followed by WHIM18 and then WHIM16 (Fig. 6b,c).
Further, both PI3K and mTOR inhibitors signiﬁcantly
reduced AKT p.S473 (Fig. 7c). Our treatment results showed
that the magnitude of drug response may be associated with
overexpression and phosphorylation of the downstream
signalling targets such as AKT proteins.
In addition to this validation of druggable hypotheses in
luminal tumours, our previous report also demonstrated the
effectiveness of combinatorial therapy of AKT and mTOR
inhibitors in two other basal breast cancer xenografts35. One of
the treated xenografts, WHIM4, was also characterized in this
study, and showed copy-number ampliﬁcation of PIK3CA and
AKT3 protein outlier expression (Fig. 6). Overall, proteogenomic
analysis revealed that the dual activation of PIK3CA at the
genomic level and AKTs at the protein level may be a common
signature of breast tumours, affecting more than 20% of PDXs in
this cohort. Importantly, our results demonstrate the potential
utility of combinatorial inhibitor treatments to treat breast
tumours showing these proteogenomic signatures.
Discussion
Breast cancer has been traditionally characterized in the clinic
through hormone receptor status and selected genes’ expres-
sions20,36, and more recently by genomic sequencing3. However,
druggable genomic driver events are detectable in only a limited
percentage of patients3. As the majority of drugs target proteins, a
systematic evaluation of breast cancer proteomes would seem
ultimately to be necessary for selecting targeted treatment and
predicting drug response. Recent advances in MS-based
proteomics allow extensive and quantitative surveys of the
global proteome. Here, we have systematically analyzed
proteogenomic proﬁles of 22 patient-derived breast cancer
xenografts and 2 EBV-positive lymphoproliferations that are
likely artifacts of engraftment of human lymphocytes into NSG
mice.
This study shows that proteogenomic signatures of PDXs
resemble most ﬁndings from breast cancer patients. While some
discrepancies exist, we established a normalization strategy at
both the genomic and proteomic levels that enabled direct
comparison. PDX tumours recapitulated the proteomic diversity
of human breast cancers (Fig. 3). We also identiﬁed multiple
druggable targets for each tumour model (Fig. 6; Supplementary
Data 17). Proteomic events validated a signiﬁcant number of
CNV or mRNA up-regulations. For example, HER2 protein and
phosphosite outlier expression was observed in HER2-E WHIM8
and WHIM35 (Fig. 5), which were effectively treated using
lapatinib (Fig. 7b). Interestingly, we also identiﬁed overexpressed
proteomic events not evident in the genomic level in both PDX
and human samples, including outlier protein expression of
EGFR, and outlier phosphosite expressions of ARAF, BRAF,
HSP90AB1, PTPN11 and TOP2A (Fig. 6), highlighting potential
new treatment opportunities in breast cancer. In the two PDX
models subsequently diagnosed as EBV-positive lymphoprolifera-
tions, we observed outlier BTK expression (Fig. 6) and activation
of the NFkB pathway (Fig. 4), validating BTK as a druggable
target in EBVþ lymphomas37. While more than 80% of the
proteomic outlier events in PDX were also found in human
tumours, a lessor 48.8% of phosphosite outlier events were
validated, potentially due to different tumour micro-
environments. Thus, transient phosphoproteomic events
identiﬁed in PDX tumours would likely require further
veriﬁcation in their corresponding primary tumours.
Outlier protein expression events can likely lead to down-
stream pathway activation, such as MET outlier protein
expression (Fig. 6) and activated Ras pathway observed in
WHIM12 (Fig. 4). While genomic analysis has utilized mutual
occurrence or exclusivity in patient cohorts to deduce pathway
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relationships, phosphorylation proﬁle analyses allowed us to
directly interrogate signalling in these established pathways in a
single sample. Our pathway activation results suggest these events
may be crucial to tumorigenesis and that some are likely the
proteomic ‘smoking guns’ that originally triggered the oncogeneic
cascade.
Roughly 77% of breast tumours showed alterations in the
PI3K-AKT signalling pathway, representing a potentially impor-
tant path forward for drug-based treatment. Yet, genomic
alterations of PI3K pathway components have not shown
themselves to predict treatment responsiveness to PI3K pathway
inhibitors32. In this study, we deﬁned complementary druggable
targets of the pathway using proteogenomic analysis, including
several events of a co-occurring PIK3CA mutation or copy-
number ampliﬁcation, and AKT protein outlier expression
coupled by elevated AKT phosphorylation. In two such breast
tumours, we successfully inhibited tumour growth using a
combination of PI3K and MTOR inhibitors (Fig. 7c). While
these results show potential functional implications, additional,
systematic treatment experiments are required to validate the
identiﬁed proteomic druggable targets.
In conclusion, this initial work using proteogenomic integra-
tion coupled with patient-derived xenograft validation, has
demonstrated a strategy that, in principle, may enable more
accurate prediction of the efﬁcacy of mechanism-based cancer
therapeutics.
Methods
Xenograft model generation. Patient-derived xenografts were generated from
primary or metastatic breast tumours using previously described procedures9.
All human tissues for these experiments were processed in compliance with NIH
regulations and institutional guidelines, and approved by the institutional review
board at Washington University. All animal procedures were reviewed and
approved by the institutional animal care and use committee at Washington
University in St. Louis. PDX models are available through the application to the
Human and Mouse-Linked Evaluation of Tumors core at http://digitalcommons.
wustl.edu/hamlet/.
We selected 24 of the established breast tumour samples, including 9 luminal B,
10 basal, 4 HER2-E, and 1 CLDN-low breast tumours for further proteogenomic
characterization. Receptor statuses of xenograft tumours were validated using IHC
after engraftment.
Immunohistochemistry. Xenografts were formalin-ﬁxed at least for 24 h and
parafﬁn-embedded. Sections were evaluated by hematoxylin & eosin (H&E)
staining. Immunohistochemistry (IHC) was performed on additional sections for
HER2 (Dako), Phospho-Akt (Ser473) (Cell signalling), FGFR2 (Abcam), and Raf-1
(Santa Cruz) following the manufacturer’s instructions. Western blotting of
phosphorylated HER2 (p.Y1248) was performed using antibody cat Nr-06-229
(Millipore).
In vivo drug treatment experiments. For the targeted treatment of the PI3K
pathway, PI3K alpha inhibitor TAK-117 and TORC1/2 inhibitor TAK-228 were
provided by Millennium Pharmaceuticals, Inc. The compounds were dissolved in
Peg400. Tumours were engrafted in NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice
(The Jackson Laboratory) by subcutaneous injection of 2–5 106 PDX cells in PBS
supplemented with 30% Matrigel (BD Biosciences, cat. no. 354234). When tumours
reached an average size of 250–300mm3, animals were assigned randomly to
control and various treatment groups (n¼ 8–9 each group). For treatment of
WHIM16 (passage 7), 18 (passage 8), and 20 (passage 5) were used. Tumour
bearing mice were gavaged with: (1) Peg400; (2) TAK-117, 140mg kg 1 day 1;
(3) TAK-228, 1mg kg 1 day 1; (4) TAK-117, 140mg kg 1 day 1, TAK-228,
1mg kg 1 day 1. The mice were treated on three consecutive days once daily and
then had a 4-day interval. Tumours were measured with external caliper, and
volume was calculated as (4p/3) (width/2)2 (length/2).
For the lapatinib therapeutic experiments of WHIM6 (passage 7), WHIM 14
(passage 11), WHIM 8 (passage 6) and WHIM 35 (passage 6), 1 106 tumour cells
were added to equal volume of 1:1 mixture of Matrigel and 10% RPMI plus 10%
FBS to 4th mammary fat pads in female SCID/bg mice (ENVIGO). We then
established tumours to an average volume 250–300mm3, and randomized the mice
into control and lapatinib groups. We treated the treated group mice with lapatinib
chow diet by formulating lapatinib (220mg kg 1) and processing them into food
pellets (by Research Diets Inc), which is supplied for 2 weeks. The numbers of
replicates for each group are as followed: WHIM 14 control (n¼ 6) and lapatinib
treated (n¼ 5); WHIM 6 control (n¼ 11) and lapatinib treated (n¼ 12); WHIM 8
control (n¼ 16) and lapatinib treated (n¼ 6); WHIM 35 control (n¼ 17) and
lapatinib treated (n¼ 18). We also treated WHIM14 with 100mg kg 1 lapatinib
treatment for 48 days, including both control (n¼ 8) and lapatinib treated (n¼ 9)
groups. Further, we tested the effect of trastuzumab (30mg kg 1 weekly with IP
injections) and pertuzumab (30mg kg 1 weekly with IP injections) on PDX
tumour growth for 48 days. The experimental groups are as following: control
group (n¼ 6) treated with physiological saline (vehicle); trastuzumab treated group
(n¼ 12); pertuzumab treated group (n¼ 11).
Statistical testing of the resulting data was conducted using the R programming
language. Wilcoxon rank sum test was applied to compare the fold change in
tumour volumes after two weeks in the lapatinib treatment experiment, and after
44 days or 48 days for the additional WHIM14 experiment using low-dose
lapatinib and trastuzumab/pertuzumab. One-way ANOVA was applied to compare
the treated versus control groups in the PI3K targeted-therapy experiments, and a
follow-up Tukey’s post hoc test was used for the various comparisons in PI3K
inhibition experiments. All human tissues for these experiments were processed in
compliance with NIH regulations and institutional guidelines, and approved by the
Washington University, University of North Carolina, or Baylor College of
Medicine Institutional Review Board (IRB). All animal procedures were reviewed
and approved by the institutional animal care and use committee at Washington
University in St. Louis, University of North Carolina, or Baylor College of
Medicine.
Genomic and proteomic data generation. Somatic mutation. Sequencing reads
were aligned using BWA38. Somatic variants were identiﬁed using VarScan2 (refs
39–41), GATK42 and Pindel43, and annotated based on Ensembl release 70_37. We
then ﬁltered out common variants by using variants from the 1000 Genomes and
NHLBI projects. We further eliminated mouse contamination by ﬁltering somatic
variants that were mapped to mouse reference genome. Somatic mutation calls
were validated either using a custom array or manually reviewed in IGV. The
genomic data of 17 out of the 24 PDXs have been presented before in our previous
studies6,8 (Supplementary Data 2).
Copy-number variation. The segment-based copy-number data were generated
using the whole-genome sequencing and exome sequencing data. We then
converted the segment-based copy-number data to the gene-based copy-number
data by using the RefSeq database (version 20130727). The copy-number values
were further transformed to the log-R ratio, using the cohort mean for the gene as
the reference.
mRNA expression and virus detection through RNA-seq. mRNA expression
values were calculated from mRNA sequencing data using MapSplice44,45. The
resulting RSEM values were normalized within samples to a ﬁxed upper quartile.
Upper quartile normalized RSEM data were log2 transformed and the data were
median centred by gene. To quantify virus abundance, we used the VirusScan
pipeline (https://github.com/ding-lab/VirusScan) to detect viruses by numbers of
virus-supporting reads from RNA-seq data.
LFQ proteome. Tumour Sample Generation and Protein Extraction. Patient-
derived xenograft breast tumours were processed to cryopulverized powders as
described previously46. The powders (100mg wet weight) were subjected to lysis
and protein extraction using a buffer composed of 8 M urea, 50mM Tris pH
8.0, 75mM NaCl, 1mM MgCl2, and 500 units Benzonase. Approximately 1mg
of total protein extracted was reduced with DTT and subsequently alkylated
with iodoacetamide. The proteins were then subjected to proteolysis with
endoproteinase Lys-C (Wako Chemicals, USA) forB4 h at 37 C. The solution was
diluted 4-fold with 25mM Tris pH 8.0, 1mM CaCl2 and further digested with
trypsin (Promega) for B12 h at 37 C. Digestion was stopped by the addition of
TFA to 0.4%, and the precipitate was removed by centrifugation. The peptide
solutions were desalted on Sep-Pak Light C18 cartridges (Waters) and dissolved in
30% ACN, 0.1% TFA before loading on a 300 mm Source 15 S (GE Healthcare)
column for Basic Reversed Phase Chromatography (bRPLC)47. A linear LC
gradient was performed by increasing buffer B from 0 to 70% within 60min, where
buffer A was aqueous 10mM ammonium formate, and buffer B was 90% ACN in
10mM ammonium formate. A total of 30 fractions were collected for each WHIM
sample (18 WHIMs). Five fractions were then prepared by combining non-
contiguously fractions. We analyzed an additional technical replicate for WHIM2
and WHIM16. The fractions were dried and desalted using a stop-and-go-
extraction tip (StageTip) protocol containing 4 1mm C18 extraction disk (3M).
Liquid Chromatography-Tandem Mass Spectrometry and Protein
Identiﬁcation. Sample analysis was performed via reversed phase LC-MS/MS using
a Proxeon 1000 nano LC system coupled to a Q Exactive mass spectrometer
(Thermo Scientiﬁc, San Jose, CA). The Proxeon system was conﬁgured to trap
peptides using a C18 column (3 cm 100mm i.d.) with a diverted ﬂow rate
(5 ml min 1) The trap column was placed in line with the analytical column
(15 cm 75mm i.d., 3.5 mm, 300Å particle C18, Thermo Scientiﬁc, San Jose, CA,
USA) before gradient elution of peptides. Analytical separation of all the tryptic
peptides was achieved with a linear gradient of 2–30% buffer B over 240min
(250 nlmin 1), where buffer A was aqueous 0.1% formic acid, and buffer B was
acetonitrile in 0.1% formic acid.
LC-MS experiments were performed in a data-dependent mode with Full-MS
(externally calibrated to a mass accuracy of o5 p.p.m., and a resolution of
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70,000 at m/z¼ 200) followed by HCD-MS/MS of the top 20 most intense ions.
High-energy collision activated dissociation (HCD)-MS/MS was used to fragment
peptides at a normalized collision energy of 27 eV in the presence of nitrogen. One
LC-MS run was performed for each fraction (from 1 process technical replicate),
except for WHIM2 and WHIM16 where 2 LC–MS runs were conducted (from 3
process technical replicates), resulting in the production of 100 LC–MS runs for
global peptide analysis. Mass spectra were processed, and peptide identiﬁcation was
performed using the Andromeda search engine found in MaxQuant software ver.
1.5.0.25. (Max Planck Institute, Germany). All protein database searches were
performed against the RefSeq database (version 20140707). Peptides were identiﬁed
with a target-decoy approach using a combined database consisting of reverse
protein sequences of the RefSeq human, mouse and common repository of
adventitious proteins (cRAP). The cRAP database was obtained from the Global
Proteome Machine (ftp://ftp.thegpm.org/fasta/cRAP). Peptide inference was made
with a FDR of 1% while peptides were assigned to proteins with a protein FDR of
5%. A precursor ion mass tolerance of 20 ppm was used for the ﬁrst search that
allowed for m/z retention time recalibration of precursor ions that were then
subjected to a main search using a precursor ion mass tolerance of 6 p.p.m. and a
product ion mass tolerance 0.5Da. Search parameters included up to two missed
cleavages at KR on the sequence, and oxidation of methionine, and protein N
terminus acetylation as a dynamic modiﬁcation. Carbamidomethylation of cysteine
residues was considered as a static modiﬁcation. Peptide identiﬁcations are
reported by ﬁltering of reverse and contaminant entries and assigning to their
leading razor protein according to the Occams razor principal. The mass
spectrometric data are deposited at the CPTAC Data Coordinating Center as raw
and mzML ﬁles (https://cptac-data-portal.georgetown.edu)47.
Peptide and Protein Quantitation. LFQ was performed based on peak areas. The
measured area under the curve of m/z and the retention time-aligned extracted ion
chromatograms of peptides were performed via the label-free quantitation module
in MaxQuant [ver. 1.5.0.25]48. All replicates for each PDX were included in the
LFQ experimental design with peptide-level quantitation performed using unique
and razor peptide features corresponding to identiﬁcations ﬁltered with a posterior
error probability (PEP) of 0.01, peptide FDR of 0.01 and protein FDR of 0.05. The
expression values were median centred in the Perseus software for further analysis
[version 1.5.0.9].
iTRAQ proteome and phosphoproteome. We included all 24 of the established
breast tumour samples for proteomic characterization using iTRAQ. Tumour
tissue samples were maintained in cryovials at  80 C until cryopulverization
using a CP02 Cryprep Pulverizer (Covaris, Woburn, MA). 90mg aliquots of
cryofractured material were prepared for proteomic processing in aluminum
weighing dishes on dry ice using spatulas kept cold in liquid nitrogen, with
remaining material reserved for other applications. The 90mg target was designed
to include 40mg for each of the collaborating research teams, with an anticipated
yield for each team of 1.5–2mg protein based on 4–5% recovery. To avoid
systematic bias, sample processing was block randomized, with each intrinsic
subtype proportionally represented in each processing tranche.
The reproducibility of the iTRAQ4-plex global proteome and phosphoproteome
analysis workﬂow used in this study has been extensively tested for quantitative
reproducibility both within and across laboratories in the CPTAC program14,49.
Over a period of several months 5 iTRAQ4-plex replicates were measured at each
of the 3 CPTAC proteome analysis centres. Each of these iTRAQ4-plexes contained
duplicate measurements for both a basal WHIM2 and a luminal WHIM16 PDX
samples that are also part of this study. A high degree of consistency in the number
of proteins identiﬁed and correlation in the protein expression was obtained49.
Pearson correlations for replicate proteome and phosphoproteome measurements
were very high with a R¼ 0.9 in our previous study14 and very similar to the
correlation observed here for the WHIM13 replicate measurement. These data
show that our platform provides highly reproducible quantitative measurements
for global proteomes and phosphoproteomes.
Protein extraction, digestion and iTRAQ labelling of peptides from breast
cancer tumours. Cryopulverized breast cancer tumour samples tissues (B2
combined aliquots of 90mg tissue weight each) were homogenized in 1,000 ml lysis
buffer containing 8M urea, 75mM NaCl, 1mM EDTA in 50mM Tris HCl (pH 8),
10mM NaF, phosphatase inhibitor cocktail 2 (1:100; Sigma, P5726) and cocktail 3
(1:100; Sigma, P0044), 2 mgml 1 aprotinin (Sigma, A6103), 10 mgml 1 Leupeptin
(Roche, #11017101001), and 1mM PMSF (Sigma, 78830). Lysates were centrifuged
at 20,000 g for 10min before measuring protein concentration of the clariﬁed
lysates by BCA assay (Pierce). Protein lysates were subsequently reduced with
5mM dithiothreitol (Thermo Scientiﬁc, 20291) for 45min at room temperature,
and alkylated with 10mM iodoacetamide (Sigma, A3221) for 45min in the dark.
Samples were diluted 4-fold with 50mM Tris HCl (pH 8) prior to digesting them
with LysC (Wako, 129-02541) for 4 h and trypsin (Promega, V511X) overnight at a
1:50 enzyme-to-protein ratio at room temperature overnight on a shaker.
Digested samples were acidiﬁed with formic acid (FA; Fluka, 56302) to a ﬁnal
volumetric concentration of 1% or ﬁnal pH ofB3–5, and centrifuged at 2,000 g for
5min to clear precipitated urea from peptide lysates. Samples were desalted on C18
SepPak columns (Waters, 100mg, WAT036820) and 1mg peptide aliquots were
dried down using a SpeedVac apparatus.
Construction of the Common internal Reference Pool. The proteomic and
phosphoproteomic analyses of xenograft samples were performed as iTRAQ 4-plex
experiments. Quantitative comparison between all samples analyzed was facilitated
by the use of iTRAQ reporter ion ratios between each individual sample and a
common internal reference sample present in each 4-plex. The reference sample
was comprised of 16 of the 24 WHIM tumours analyzed in this study with equal
contribution for each tumour (WHIM numbers 2, 4, 6, 8, 11, 12, 13, 14, 16, 18, 20,
21, 24, 25, 30 and 46). The 24 tumour samples were analyzed in nine independent
4-plex experiments, with three individual samples occupying the ﬁrst three
channels of each experiment and the 4th channel being reserved for the reference
sample. While eight iTRAQ 4-plex experiments were used to analyze the 24
individual WHIM tumour samples, an additional 4-plex experiment was designed
to include the WHIM13 sample for process replicate analysis and also internal
reference samples from our human primary breast cancer study14 and a taxol
drug response study (unpublished) to allow cross-referencing of the different
datasets.
iTRAQ labelling, high pH reversed-phase separation and phosphopeptide
enrichment of peptide samples. Desalted peptides were labelled with 4-plex iTRAQ
reagents according to the manufacturer’s instructions (AB Sciex, Foster City, CA).
For each 1mg peptide from each breast tumour sample, 10 units of labelling
reagent were used. Peptides were dissolved in 300ml of 0.5 M triethylammonium
bicarbonate (TEAB) (pH 8.5) solution and labelling reagent was added in 700 ml of
ethanol. After 1 h incubation, 1.5ml of 0.05% TFA was added to stop the reaction.
Differentially labelled peptides were mixed and subsequently desalted on 500mg
tC18 SepPak columns. The combined 4mg iTRAQ samples per experiment were
separated into 24 proteome fractions and 12 phosphoproteome fractions using a
4.6mm 250mm column RP Zorbax 300 A ExtendC18 column (Agilent, 3.5 mm
bead size) on an Agilent 1100 Series HPLC instrument by basic reversed-phase
chromatography as described previously46. Peptides were separated according to
their hydrophobicity using solvent A (2% acetonitrile, 5mM ammonium formate,
pH 10) and a nonlinear increasing concentration of solvent B (90% acetonitrile,
5mM ammonium formate, pH 10). Phosphopeptides were enriched using Ni-NTA
superﬂow agarose beads (Qiagen, #1018611) that were stripped of nickel with
100mM EDTA and incubated in an aqueous solution of 10mM FeCl3 (Sigma,
451649) as described previously50. For phosphopeptide enrichment a 80%
acetonitrile/0.1% triﬂuoroacetic acid binding buffer and a 500mM dibasic sodium
phosphate, pH 7.0, (Sigma, S9763) elution buffer were used. Enriched samples were
desalted on StageTips as described50 before analysis by LC–MS/MS.
Analysis of tumour samples by high performance liquid chromatography
tandem mass spectrometry (LC–MS/MS). All peptides were separated with an
online nanoﬂow Proxeon EASY-nLC 1000 UHPLC system (Thermo Fisher
Scientiﬁc) and analyzed on a benchtop Orbitrap Q Exactive mass spectrometer
(Thermo Fisher Scientiﬁc) equipped with a nanoﬂow ionization source (James A.
Hill Instrument Services, Arlington, MA, USA). The LC system, column, and
platinum wire to deliver electrospray source voltage were connected via a stainless-
steel cross (360 mm, IDEX Health & Science, UH-906x). The column was heated to
50 C using a column heater sleeve (Phoenix-ST) to prevent overpressurizing of
columns during UHPLC separation. 10% of each global proteome sample in a 2 ml
injection volume, or 50% of each phosphoproteome sample in a 4 ul injection
volume was injected onto an in-house packed 20 cm 75 um diameter C18 silica
picofrit capillary column (1.9 mm ReproSil-Pur C18-AQ beads, Dr Maisch GmbH,
r119.aq; Picofrit 10 um tip opening, New Objective, PF360-75-10-N-5). Mobile
phase ﬂow rate was 200 nlmin 1, comprised of 3% acetonitrile/0.1% formic acid
(Solvent A) and 90% acetonitrile /0.1% formic acid (Solvent B), and the 110-minute
LC-MS/MS method consisted of a 10-min column-equilibration procedure, a 20-
min sample-loading procedure, and the following gradient proﬁle: (min:%B) 0:2;
1:6; 85:30; 94:60; 95;90; 100:90; 101:50; 110:50 (last two steps at 500 nlmin 1
ﬂowrate). Data-dependent acquisition was performed using Xcalibur QExactive
v2.1 software in positive ion mode at a spray voltage of 2.00 kV. MS1 Spectra were
measured with a resolution of 70,000, an AGC target of 3e6 and a mass range from
300 to 1,800m/z. Up to 12 MS2 spectra per duty cycle were triggered at a resolution
of 17,500, an AGC target of 5e4, an isolation window of 2.5m/z, a maximum ion
time of 120msec, and a normalized collision energy of 28. Peptides that triggered
MS2 scans were dynamically excluded from further MS2 scans for 20 s. Charge
state screening was enabled to reject precursor charge states that were unassigned,
1, or46. Peptide match was enabled for monoisotopic precursor mass assignment.
Protein-peptide identiﬁcation, phosphosite localization, and quantitation. All
MS data were interpreted using the Spectrum Mill software package v5.1 (for
comparison with proteomes of human breast tumours from our previous study14)
and v6.0 pre-release (Agilent Technologies, Santa Clara, CA, USA) co-developed by
the authors. Similar MS/MS spectra acquired on the same precursor m/z within±
45 s were merged. MS/MS spectra were excluded from searching if they failed
the quality ﬁlter by not having a sequence tag length40 (that is, minimum of two
masses separated by the in-chain mass of an amino acid) or did not have a
precursor MHþ in the range of 750–6,000. MS/MS spectra from were
searched against a database consisting of RefSeq release 60 containing 31,767
human proteins, 24,821 mouse proteins, and an appended set of 85
common laboratory contaminant proteins (RefSeq.20130727-Human.20130730-
MouseNR.mm13.contams). Scoring parameters were ESI-QEXACTIVE-HCD-v2,
for whole proteome datasets, and ESI-QEXACTIVE-HCD-v3 parameters were for
phosphoproteome datasets. All spectra were allowed ±20 p.p.m. mass tolerance
for precursor and product ions, 40% minimum matched peak intensity, and trypsin
allow P enzyme speciﬁcity with up to four missed cleavages. Fixed modiﬁcations
were carbamidomethylation at cysteine. iTRAQ labelling was required at lysine, but
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peptide N-termini were allowed to be either labelled or unlabelled. Allowed
variable modiﬁcations for whole proteome datasets were acetylation of protein
N-termini, oxidized methionine, deamidation of asparagine, pyro-glutamic acid at
peptide N-terminal glutamine, and pyro-carbamidomethylation at peptide
N-terminal cysteine with a precursor MHþ shift range of  18 to 64Da. Allowed
variable modiﬁcations for phosphoproteome dataset were revised to disallow
deamidation and allow phosphorylation of serine, threonine, and tyrosine with a
precursor MHþ shift range of 0 to 272Da.
Identities interpreted for individual spectra were automatically designated as
conﬁdently assigned using the Spectrum Mill autovalidation module to use target-
decoy based FDR estimates to apply score threshold criteria via two-step strategies.
For the whole proteome datasets thresholding was done at the spectral and protein
levels. For the phosphoproteome datasets thresholding was done at the spectral
level. In step 1, peptide autovalidation was done ﬁrst and separately for each
iTRAQ 4-plex experiment consisting of either 25 LC–MS/MS runs (whole
proteome) or 13 LC–MS/MS runs (phosphoproteome) using an auto thresholds
strategy with a minimum sequence length of 7(whole proteome) or 8
(phosphoproteome), automatic variable range precursor mass ﬁltering, and score
and delta Rank1–Rank2 score thresholds optimized to yield a spectral level FDR
estimate for precursor charges 2 through 4 of o0.6% for each precursor charge
state in each LC–MS/MS run. For precursor charges 5–6, thresholds were
optimized to yield a spectral level FDR estimate of o0.3% across all runs per
iTRAQ 4-plex experiment (instead of each run), to achieve reasonable statistics,
since many fewer spectra are generated for the higher charge states.
In step 2 for the whole proteome datasets, protein polishing autovalidation was
applied separately to each iTRAQ 4-plex experiment to further ﬁlter the PSM’s
using a target protein-level FDR threshold of zero. The primary goal of this step
was to eliminate peptides identiﬁed with low scoring peptide spectrum matches
(PSM’s) that represent proteins identiﬁed by a single peptide, so-called ‘one-hit
wonders’. After assembling protein groups from the autovalidated PSM’s, protein
polishing determined the maximum protein level score of a protein group that
consisted entirely of distinct peptides estimated to be false-positive identiﬁcations
(PSM’s with negative delta forward-reverse scores). PSM’s were removed from the
set obtained in the initial peptide-level autovalidation step if they contributed to
protein groups that have protein scores below the max false-positive protein score.
In the ﬁltered results each identiﬁed protein detected in an iTRAQ 4-plex
experiment was comprised of multiple peptides unless a single excellent scoring
peptide was the sole match. For the whole proteome datasets the above criteria
yielded FDR of o0.5% at the peptide-spectrum match level and o0.8% at the
distinct peptide level for each iTRAQ 4-plex experiment. After assembling proteins
with all the PSMs from all the iTRAQ 4-plex experiments together the aggregate
FDR estimates were 0.42% at the at the peptide-spectrum match level, 1.5% at the
distinct peptide level, and o0.01% (1/11,372) at the protein group level. Since the
protein level FDR estimate neither explicitly required a minimum number of
distinct peptides per protein nor adjusted for the number of possible tryptic
peptides per protein, it may underestimate false positive protein identiﬁcations for
large proteins observed only on the basis of multiple low scoring PSMs.
In calculating scores at the protein level and reporting the identiﬁed proteins,
redundancy was addressed in the following manner: the protein score was the sum
of the scores of distinct peptides. A distinct peptide was the single highest scoring
instance of a peptide detected through an MS/MS spectrum. MS/MS spectra for a
particular peptide may have been recorded multiple times, (that is, as different
precursor charge states, in adjacent bRP fractions, modiﬁed by deamidation at Asn
or oxidation of Met, or different phosphosite localization) but were still counted as
a single distinct peptide. When a peptide sequence48 residues long was contained
in multiple protein entries in the sequence database, the proteins were grouped
together and the highest scoring one and its accession number were reported. In
some cases when the protein sequences were grouped in this manner there were
distinct peptides that uniquely represented a lower scoring member of the group
(isoforms, family members, and different species). Each of these instances spawned
a subgroup. Multiple subgroups were reported and counted towards the total
number of proteins, and were given related protein subgroup numbers (for
example, 3.1 and 3.2: group 3, subgroups 1 and 2). To better dissect the tumour/
stroma (human/mouse) origin of orthologous proteins in this xenograft
experiment, the inclusion of peptides contributing to each subgroup was restricted
by enabling the subgroup-speciﬁc (SGS) option in Spectrum Mill. Only subgroup-
speciﬁc peptide sequences were counted toward each subgroup’s count of distinct
peptides and protein level TMT quantitation. The SGS option omits peptides that
are shared between subgroups. If evidence for BOTH human and mouse peptides
from an orthologous protein were observed, then peptides that cannot distinguish
the two (shared) were ignored. However, the peptides shared between species were
retained if there was speciﬁc evidence for only one of the species, thus yielding a
single subgroup attributed to only the single species consistent with the speciﬁc
peptides. Furthermore, if all peptides observed for a protein group were shared
between species, thus yielding a single subgroup composed of indistinguishable
species, then all peptides were retained (the column in Supplementary Data 3
numSpeciesPresentR1 will have a value of 2 in such cases). Assembly of conﬁdently
identiﬁed PSM’s yielded 20,480 total protein subgroups from 11,372 protein
groups. Human and mouse ortholog proteins were typically arranged into
individual subgroups.
In step 2 for the phosphoproteome datasets a phosphosite table were assembled
with columns for individual iTRAQ 4-plex experiments and rows for individual
phosphosites. PSM’s were combined into a single row for all non-conﬂicting
observations of a particular phosphosite. (that is, different missed cleavage forms,
different precursor charges, conﬁdent and ambiguous localizations, different
sample handling modiﬁcations). For related peptides neither observations with a
different number of phosphosites nor different conﬁdent localizations were allowed
to be combined. Selecting the representative peptide from the combined
observations was done such that once conﬁdent phosphosite localization was
established, higher identiﬁcation scores and longer peptide lengths are preferable.
After assembling the phosphosite table a polishing step was applied to further ﬁlter
the phosphosites with the primary goal of eliminating phosphosites with
representative peptides identiﬁed through low scoring peptide spectrum matches
(PSM’s) that were observed in only a few experiments. The initial table of
representative peptides for 82,030 phosphosites had an aggregate FDR of 3.3% at
phosphosite-level. The table was sorted by identiﬁcation score and then by number
of iTRAQ 4-plex experiments in which the phosphosite was observed. The
cumulative FDR trend showed inﬂection points at an identiﬁcation score of B8.
Phosphosites with an identiﬁcation scoreo8.0 observed ino3/9 experiments were
therefore removed, yielding 68,385 phosphosites with an aggregate FDR of 0.34% at
the phosphosite level. While the Spectrum Mill identiﬁcation score is based on the
number of matching peaks, their ion type assignment, and the relative height of
unmatched peaks, the phosphosite localization score is the difference in
identiﬁcation score between the top two localizations. The score threshold for
conﬁdent localization (41.1) essentially corresponds to at least 1 b or y ion located
between two candidate sites that has a peak height 10% of the tallest fragment ion
(neutral losses of phosphate from the precursor and related ions as well as
immonium and iTRAQ reporter ions are excluded from the relative height
calculation). The ion type scores for b-H3PO4, y-H3PO4, b-H2O, and y-H2O ion
types are all set to 0.5. This prevents inappropriate conﬁdent localization
assignment when a spectrum lacks primary b or y ions between two possible sites
but contains ions that can be assigned as either phosphate loss ions for one
localization or water loss ions for another localization. In aggregate, 66.3% of the
reported phosphosites were fully localized to a particular serine, threonine, or
tyrosine residue.
Relative abundances of proteins and phosphosites were determined in Spectrum
Mill using iTRAQ reporter ion intensity ratios from each PSM. A protein-level or
phosphosite-level iTRAQ ratio was calculated as the median of all PSM level ratios
contributing to a protein subgroup or phosphosite remaining after excluding those
PSM’s lacking an iTRAQ label, having a negative delta forward-reverse score (half
of all false-positive identiﬁcations), or having a precursor ion purityo50% (MS/MS
has signiﬁcant precursor isolation contamination from co-eluting peptides). Unless
stated otherwise for a particular analysis, the following considerations apply to the
tumour/stroma (human/mouse) origin of a protein in this xenograft experiment.
For the proteome dataset, only PSM’s from subgroup-speciﬁc peptide sequences
contributed to the protein level quantitation (see protein subgrouping description
above). A protein detected with all contributing PSM’s shared between human and
mouse was considered to be human. For the phosphoproteome dataset, a
phosphosite was considered to be mouse if the contributing PSM’s were distinctly
mouse and human if they were either distinctly human or shared between human
and mouse. A 2-component Gaussian mixture model-based normalization
approach was used to centre the distribution of iTRAQ log-ratios around zero to
nullify the effect of differential protein loading and/or systematic MS variation14.
Downstream analyses presented in the main ﬁgures were restricted to proteins/
phosphosites quantiﬁed in at least 10 out of the 24 samples with non-missing
values (Supplementary Fig. 3), with the exception of the previously described
mRNA-protein correlation analysis13 requiring quantiﬁcation in 30%, or 8 out of
24, PDX samples. Speciﬁc ﬁltering procedures are noted in descriptions of the
relevant methods.
Bioinformatics analyses. Cross data-type integration. All gene names were con-
verted to HUGO Gene Nomenclature Committee’s approved gene names for
comparison across levels and datasets. For mRNA and protein expressions,
expression values were collapsed across transcripts or isoforms to the corre-
sponding gene using the highest mean when there were two transcripts or isoforms,
or the value with the highest connectivity when there were more than three
transcripts or isoforms as implemented in the WGCNA R package51.
mRNA-protein correlation. Spearman correlations between normalized RSEM
values and protein quantiﬁcations were calculated for genes that were observed in
at least 30% of samples for both RNA-seq and mass-spectrometry as previously
described. KEGG pathway enrichment analysis of the correlation was carried out
using a Kolmogorov–Smirnov test, and P values were adjusted using the
Benjamini-Hochberg procedure.
Proteomic clustering and subtyping. We ﬁrst applied ﬁltering for protein and
phosphosite markers observed in at least 10 samples and sufﬁcient deviations
across samples. We used a 2 s.d. threshold for iTRAQ proteome and 2.5 s.d. for the
phosphoproteome. We applied the same protein marker to conduct LFQ proteome
and PDX vs. human proteome co-clustering. For the co-clustering with human
proteome, we further selected for markers that had higher than 2 s.d.’s in the
merged proteome and showed non-differential expression between human and
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PDX (FDR40.3, t-test). The subsequent hierarchical clustering was conducted
using the complete agglomeration method of hclust as implemented in the
heatmap2 R package.
Differential expression analysis. Differential expression testing of each protein in
the LFQ and iTRAQ datasets was conducted using the student’s t-test, and P values
were adjusted using the Benjamini-Hochberg procedure. For gene set enrichment
analysis, we conducted the Wilcoxon Rank Sum Test to test for changes in the
t-statistics ranks of protein members in each of the KEGG signalling pathway, and
again adjusted P values using the Benjamini-Hochberg procedure.
Druggable genes and mutations. We compiled a list of druggable genes based on
extensive curation of public databases: Tumor Alterations Relevant for GEnomics-
driven Therapy (TARGET, version 3, assessed on 6/15/2015), Personalized Cancer
Therapy (PCT, assessed on 3/15/2015), GDKD (Gene-Drug Knowledge Database,
version 11.0, assessed on 4/10/2015), CancerDR (assessed on 2/6/2015), My Cancer
Genome (assessed on 9/11/2014), and DrugBank (assessed on 9/21/2015). We
curated the list based on evidence level and literature, as well as IC50 data when
available. The ﬁnal list used for the analysis included 76 druggable genes
(Supplementary Data 15).
Druggable outlier analysis. To discover expression outliers, we utilized a strategy
incorporating multiple steps: ﬁrst, we limited our search to genes that are in the
druggable gene list. We then narrowed down the list to genes that are observed in
at least 10 samples in the dataset under investigation. Outlier expressions were
deﬁned as values that are greater than 1.5 interquartile ranges (IQRs) above the
third quartile (Q3). To rank order outlier expression for each gene, we calculated
an outlier score deﬁned as:
Outlier score ¼ x  Q3ð Þ=IQR
By deﬁnition, genes with outlier score greater than 1.5 are considered as expression
outliers. Outlier score for each gene were ranked within the sample to select the
most promising druggable targets. For CNV outliers, we required them to have
outlier scores above 1 in at least another expression level. For validation of the
proteomic druggable outliers, we counted the numbers of the same protein or
phosphosite outliers observed in the parallel-processed cohort of 77 human breast
cancer samples. Due to the lower numbers in this larger cohort, we considered both
proteins with outlier score greater than 1 and the top 2 outliers of each human
sample as validating outliers.
Pathway activation analysis. We ﬁrst collapsed the phosphosites to gene-level
phosphorylation values by averaging the phosphosite expressions observed for each
gene. Then, we converted the phosphoproteomic expression values from iTRAQ to
modiﬁed z-scores normalized against the cohort as described in Hoaglin et al.
(How to Detect and Handle Outliers). We then used the Wilcoxon Rank Sum Test
to test for changes in the phosphorylation z-score ranks of protein members in
each of the KEGG signalling pathway. The resulting P values were adjusted using
the Benjamini–Hochberg procedure.
Data availability. All mass spectra, in the original instrument vendor format,
contributing to this study may be downloaded from: https://cptac-data-portal.
georgetown.edu/cptacPublic/ for the study name: TCGA Breast Cancer.
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